Hero

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

1

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

2

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

3

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Discover all news

Carousel

Social Feed

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

2 days ago

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

RT @LifeSciComms: At #JPM20, Filippo Petti, @CelyadSA CEO, spoke with Benjamin Roberts from @Biotech_finance about #Celyad’s CAR-T #CellThe…

6 days ago

RT @LifeSciComms: At #JPM20, Filippo Petti, @CelyadSA CEO, spoke with Benjamin Roberts from @Biotech_finance about #Celyad’s CAR-T #CellThe…

RT @LifeSciComms: CEO of @CelyadSA, Filippo Petti, talked about the value that both personalized (autologous) & off-the-shelf (allogeneic)…

1 week ago

RT @LifeSciComms: CEO of @CelyadSA, Filippo Petti, talked about the value that both personalized (autologous) & off-the-shelf (allogeneic)…

RT @DriesDeeren: Amazing how such an incredibly advanced therapy can be delivered in such a straightforward way, thanks to a dedicated team…

1 week ago

RT @DriesDeeren: Amazing how such an incredibly advanced therapy can be delivered in such a straightforward way, thanks to a dedicated team…

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

2 days ago

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

RT @LifeSciComms: At #JPM20, Filippo Petti, @CelyadSA CEO, spoke with Benjamin Roberts from @Biotech_finance about #Celyad’s CAR-T #CellThe…

6 days ago

RT @LifeSciComms: At #JPM20, Filippo Petti, @CelyadSA CEO, spoke with Benjamin Roberts from @Biotech_finance about #Celyad’s CAR-T #CellThe…

RT @LifeSciComms: CEO of @CelyadSA, Filippo Petti, talked about the value that both personalized (autologous) & off-the-shelf (allogeneic)…

1 week ago

RT @LifeSciComms: CEO of @CelyadSA, Filippo Petti, talked about the value that both personalized (autologous) & off-the-shelf (allogeneic)…

RT @DriesDeeren: Amazing how such an incredibly advanced therapy can be delivered in such a straightforward way, thanks to a dedicated team…

1 week ago

RT @DriesDeeren: Amazing how such an incredibly advanced therapy can be delivered in such a straightforward way, thanks to a dedicated team…